Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd is in the business of TPP and its allied products[1]
- Market Cap ₹ 42.5 Cr.
- Current Price ₹ 54.0
- High / Low ₹ 115 / 47.3
- Stock P/E 20.8
- Book Value ₹ 22.2
- Dividend Yield 0.00 %
- ROCE 12.1 %
- ROE 12.3 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 10.8% over last 3 years.
- Earnings include an other income of Rs.2.08 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
29 | 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 121 | 121 | |
29 | 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 117 | 117 | |
Operating Profit | -0 | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 |
OPM % | -1% | 7% | -3% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 3% | 4% |
0 | -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | |
Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | -2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
Tax % | 3% | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | 25% | |
-2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | |
EPS in Rs | -2.56 | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.58 | 2.60 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 34% |
3 Years: | 33% |
TTM: | 35% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 41% |
3 Years: | 26% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 43% |
3 Years: | -3% |
1 Year: | -32% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 10% |
3 Years: | 11% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 10 |
8 | 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 33 | |
7 | 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 26 | |
Total Liabilities | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 |
8 | 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | |
CWIP | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
16 | 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | |
Total Assets | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | -3 | -7 | |
-0 | -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | 2 | |
-0 | -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | 3 | 5 | |
Net Cash Flow | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 88 | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 | 39 |
Inventory Days | 94 | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 | 121 |
Days Payable | 118 | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 | 56 |
Cash Conversion Cycle | 65 | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 | 104 |
Working Capital Days | 15 | 32 | 69 | 114 | 214 | 108 | 104 | 114 | 37 | 1 | 10 | 36 |
ROCE % | -4% | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 12% | 12% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting
2d - Appointed two Independent Additional Directors, cost auditor; approved AGM on 30 Sep 2025; e-voting 26-29 Sep; cut-off 20 Sep.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Appointed two independent directors effective 01/10/2025–30/09/2030; AGM 30 Sep 2025; cost auditor FY2025-26.
- 40Th Annual General Meeting (AGM) Of The Company Scheduled To Be Held On Tuesday, The 30Th September, 2025 At 10.00 A.M. (IST) Through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). 2d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Aug - Submission of Newspaper clipping w.r.t publication of Unaudited Financial Results for the quarter ended 30/06/2025 in Business Standard and Andhra Prabha on 15th August 2025
-
Unaudited Financial Results For The Quarter Ended 30Th June 2025
14 Aug - Roopa Industries Q1 FY2026 unaudited results: Rs 3507L revenue, Rs 28L profit, limited review done.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2][3][4]
RIL manufactures Bulk Drugs, Drug Intermediates, Nutraceuticals, and fine chemicals. It produces Active Pharmaceutical Ingredients such as Fluconazole, Sildenafil Citrate, Losartan Potassium and Triphenyl Phosphine (which goes into production of Cephalosporins, Statins etc.,) and Nutraceuticals such as Glucosamine salts.
Its products are used in chemical and pharmaceutical industry and supplied globally